Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

104.01 -0.25 (-0.24%)
Streaming Delayed Price Updated: 12:55 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ligand Pharm

< Previous 1 2 3 Next >
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Appoints Martine Zimmermann to its Board of Directors
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Second Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand To Report Second Quarter 2023 Financial Results On August 8
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
From Novan, Inc.
Via GlobeNewswire
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports First Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Fourth Quarter Financial Results on February 22
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Provides Highlights from its Investor and Analyst Day Event
From Ligand Pharmaceuticals
Via Business Wire
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Hold Investor and Analyst Day on December 13
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Third Quarter 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Announces Completion of OmniAb Spin-Off
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Distribution of OmniAb Complete and Business Combination Closed
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Third Quarter Financial Results on November 7
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
OmniAb Business Combination Approved by APAC Shareholders
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
From Ligand Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.